Impact of SPR biosensor assay configuration on antibody: Neonatal Fc receptor binding data

Wang, Xiangdan; McKay, Patrick; Yee, Liliana T; Dutina, George; Hass, Philip E.; Nijem, Ihsan; Allison, David E.; Cowan, Kyra J.; Lin, Kevin K.; Quarmby, Valerie; Yang, Jihong

doi:10.1080/19420862.2016.1261774

Cited by 21 publications

(18 citation statements)

References 59 publications

(103 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The development of SPR is important in many fields such as agricultural and food safety [1], medical diagnosis [2], environmental safety control [3] and industrial monitoring [4]. The major application of SPR biosensor is for detection of a variety of biomolecules such as lipid [5], peptides [6], receptor [7], nucleic acid [8], protein [9] and antibodies [10]. The SPR technique has not only been used for biosensing purposes but also in characterizing a broad range of material thin films [11].…”

Section: Introductionmentioning

confidence: 99%

ZnO for performance enhancement of surface plasmon resonance biosensor: a review

Mei

Menon

Hegde³

2020

Mater. Res. Express

View full text Add to dashboard Cite

This paper reviews Kretschmann-based SPR sensor utilizing ZnO thin films and nanostructures for performance enhancement. The advancement in surface plasmon resonance technology relies on low-cost, high sensitivity and high selectivity sensor. Metal oxide has been incorporated in SPR sensor to be used for detection of biological and chemical compounds. ZnO as one of the metal oxides is an attractive material due to its unique physical and optical properties. Numerous techniques for fabrication and characterization of ZnO on SPR gold substrate have been studied. The mechanism for gas and biomolecules detection depends on their interaction with ZnO surface, which is mainly attributed to the high isoelectric point of ZnO. There are several types of ZnO nanostructures which have been employed for SPR application based on the Kretschmann configuration. In future, the thin film and nanostructures of ZnO have potential applications for miniature design, robust, high sensitivity, and low-cost portable type of SPR biosensor to be used for on-site testing in real-time and label-free manner.

show abstract

Section: Introductionmentioning

confidence: 99%

ZnO for performance enhancement of surface plasmon resonance biosensor: a review

Mei

Menon

Hegde³

2020

Mater. Res. Express

View full text Add to dashboard Cite

show abstract

“…As there are no clear regulatory guidelines in this area, each individual laboratory tends to apply its own practices. This has sometimes resulted in dramatically different information [3,4] which not only makes it difficult to compare MIC data between laboratories, but could also add confusion and delays in the drug development.…”

Section: Introductionmentioning

confidence: 99%

“…Additionally, in the process of recombinant protein production, protein misfolding and post-translational modifications may occur, providing potentially biased binding properties compared with proteins naturally expressed by cells. Furthermore, considerations should be taken when designing an SPR assay and interpreting the results since the immobilization or capture steps could modify the binding properties of the ligand protein [3,4].…”

Section: Introductionmentioning

confidence: 99%

Molecular Interaction Characterization Strategies for the Development of New Biotherapeutic Antibody Modalities

Wang¹,

Phan²,

Li³

et al. 2020

Antibodies

Self Cite

View full text Add to dashboard Cite

The characterization of target binding interactions is critical at each stage of antibody therapeutic development. During early development, it is important to design fit-for-purpose in vitro molecular interaction characterization (MIC) assays that accurately determine the binding kinetics and the affinity of therapeutic antibodies for their targets. Such information enables PK/PD (pharmacokinetics/pharmacodynamics) modeling, estimation of dosing regimens, and assessment of potency. While binding kinetics and affinities seem to be readily obtained, there is little discussion in the literature on how the information should be generated and used in a systematic manner along with other approaches to enable key drug development decisions. The introduction of new antibody modalities poses unique challenges to the development of MIC assays and further increases the need to discuss the impact of developing context-appropriate MIC assays to enable key decision making for these programs. In this paper, we discuss for the first time the challenges encountered when developing MIC assays supporting new antibody modalities. Additionally, through the presentation of several real case studies, we provide strategies to overcome these challenges to enable investigational new drug (IND) filings.

show abstract

“…However, differences were observed in the binding of 2G12 and PG16 when the CHO-and 335 Expi293F-derived gp145s were immobilized onto the sensor (Table 3). These apparent discrepancies 336 in binding values depending on the assay orientation are not uncommon [42]. When bNAbs are 337 captured on an anti-human Fc sensor, the antibody molecules are oriented in the same fashion 338 exposing the antigen binding region in an optimal and uniform manner.…”

mentioning

confidence: 99%

“…When bNAbs are 337 captured on an anti-human Fc sensor, the antibody molecules are oriented in the same fashion 338 exposing the antigen binding region in an optimal and uniform manner. Thus, it is not surprising that 339 higher affinities were obtained when the antibodies were captured, than when the antigen is 340 immobilized in a random orientation [42].…”

mentioning

confidence: 99%

A recombinant gp145 Env glycoprotein from HIV-1 expressed in two different cell lines: effects on glycosylation and antigenicity

González-Feliciano

Akamine

Capó-Vélez

et al. 2020

Preprint

View full text Add to dashboard Cite

24 Short title: Glycosylation and antigenicity of gp145 uncleaved trimers 25 26 2 27 Abstract 28The envelope glycoprotein (Env) of the human immunodeficiency virus (HIV), has been the 29 primary target for the development of a protective vaccine against infection. The extensive N-linked 30 glycosylation on Env is an important consideration as it may affect efficacy, stability, and expression 31 yields. The expression host has been shown to influence the extent and type of glycosylation that 32 decorates the protein target. Here, we report the glycosylation profile of the candidate subtype C 33 immunogen CO6980v0c22 gp145 produced in two different host cells: CHO-K1 and Expi293F. The 34 amino acid sequence for both glycoproteins was confirmed to be identical by peptide mass 35 fingerprinting. However, the isoelectric point of the proteins differed; 4.5-5.5 and 6.0-7.0 for gp145 36 produced in CHO-K1 and Expi293F, respectively. These differences in pI were eliminated by 37 enzymatic treatment with sialidase, indicating a large difference in the incorporation of sialic acid 38 between hosts. This dramatic difference in the number of sialylated glycans between hosts was 39 confirmed by analysis of PNGase F-released glycans using MALDI-ToF MS. These differences in 40 glycosylation, however, did not greatly translate into differences in antibody recognition. Biosensor 41 assays showed that gp145 produced in CHO-K1 had similar affinity toward the broadly neutralizing 42 antibodies, 2G12 and PG16, as the gp145 produced in Expi293F. Additionally, both immunogens 43 showed the same reactivity against plasma of HIV-infected patients. Taken together, these results 44 support the notion that there are sizeable differences in the glycosylation of Env depending on the 45 expression host. How these differences translate to vaccine efficacy remains unknown. 46 47 48 49 Introduction 50 With 35 million infected individuals worldwide, the human immunodeficiency virus (HIV)51 remains a major global health concern. Most of the current efforts toward a protective vaccine against 52 HIV center on the envelope glycoprotein (Env), the only protein displayed on the virus surface [1-5].53 Env is a two-protein system composed of a monomeric gp120 that binds non-covalently to the 54 trimeric, membrane-spanning gp41 [6,7]. Env-based vaccines are notoriously difficult to produce 55 because of their hydrophobic membrane-proximal regions and their extensive glycosylation [8].56 Despite these production hurdles, monomeric gp120 has been produced in large amounts and has been 57 thoroughly tested in numerous vaccine trials, including the landmark RV144 vaccine trial in Thailand 58 [9][10][11]. 59After the discovery of patient-derived broadly neutralizing antibodies (bNAbs), which 60 provide cross-clade protection through specific recognition of the viral Env, it was clear that the 61 monomeric gp120 did not contain all the relevant epitopes to elicit broad neutralization, and thus, 62 longer Env constructs to preserve known bNAb epitopes within the...

show abstract

Impact of SPR biosensor assay configuration on antibody: Neonatal Fc receptor binding data

Cited by 21 publications

References 59 publications

ZnO for performance enhancement of surface plasmon resonance biosensor: a review

ZnO for performance enhancement of surface plasmon resonance biosensor: a review

Molecular Interaction Characterization Strategies for the Development of New Biotherapeutic Antibody Modalities

A recombinant gp145 Env glycoprotein from HIV-1 expressed in two different cell lines: effects on glycosylation and antigenicity

Contact Info

Product

Resources

About